Filing Flows › ELI Lilly (LLY) › Q3 2026 › vs Q2 2026
ELI Lilly (LLY) Q3 2026 vs Q2 2026 (quarter over quarter)
ELI Lilly's revenue rose $1.4B (+6%) from $23.0B in Q2 2026 to $24.4B in Q3 2026. Operating margin 34.5% against 40.2% (-5.8 pts).
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 34.5% | 40.2% | -5.8 pts |
| Net margin | 26.4% | 30.9% | -4.4 pts |
| Free cash flow margin | 33.7% | 33.8% | -0.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $24.4B | $23.0B | $1.4B | +6% |
| Operating profit | $8.4B | $9.2B | −$841M | -9% |
| Costs & expenses | $16.0B | $13.7B | $2.3B | +16% |
| Pre-tax earnings | $8.4B | $9.2B | −$841M | -9% |
| Cost of revenue | $3.9B | $3.3B | $665M | +20% |
| Research & development | $4.2B | $3.8B | $428M | +11% |
| SG&A | $3.1B | $3.4B | −$305M | -9% |
| Other operating costs | $4.7B | $3.2B | $1.5B | +46% |
| Net earnings | $6.5B | $7.1B | −$644M | -9% |
| Income tax | $2.0B | $2.2B | −$197M | -9% |
| Depreciation & amortization | $545M | $534M | $11.0M | +2% |
| Share-based compensation | $200M | $201M | −$1.0M | -0.5% |
| Working capital & other | $4.2B | $2.9B | $1.3B | +47% |
| Operating cash flow | $11.4B | $10.7B | $707M | +7% |
| Free cash flow (OCF − capex) | $8.2B | $7.8B | $462M | +6% |
| Capital expenditures | $3.2B | $2.9B | $245M | +8% |
Questions
How much did ELI Lilly's revenue grow quarter over quarter in Q3 2026?
ELI Lilly's revenue rose $1.4B (+6%) from $23.0B in Q2 2026 to $24.4B in Q3 2026. Operating margin 34.5% against 40.2% (-5.8 pts).